JP2023551204A5 - - Google Patents

Info

Publication number
JP2023551204A5
JP2023551204A5 JP2023530750A JP2023530750A JP2023551204A5 JP 2023551204 A5 JP2023551204 A5 JP 2023551204A5 JP 2023530750 A JP2023530750 A JP 2023530750A JP 2023530750 A JP2023530750 A JP 2023530750A JP 2023551204 A5 JP2023551204 A5 JP 2023551204A5
Authority
JP
Japan
Prior art keywords
peptide
nucleic acid
acid sequence
section
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023530750A
Other languages
English (en)
Japanese (ja)
Other versions
JP7829242B2 (ja
JP2023551204A (ja
Filing date
Publication date
Priority claimed from US17/100,630 external-priority patent/US11058751B1/en
Priority claimed from US17/114,237 external-priority patent/US11161892B1/en
Priority claimed from US17/389,875 external-priority patent/US11421015B2/en
Application filed filed Critical
Priority claimed from PCT/US2021/060013 external-priority patent/WO2022109220A1/en
Publication of JP2023551204A publication Critical patent/JP2023551204A/ja
Publication of JP2023551204A5 publication Critical patent/JP2023551204A5/ja
Application granted granted Critical
Publication of JP7829242B2 publication Critical patent/JP7829242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023530750A 2020-11-20 2021-11-19 最適化ペプチドワクチンの組成物および方法 Active JP7829242B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US17/100,630 US11058751B1 (en) 2020-11-20 2020-11-20 Compositions for optimized RAS peptide vaccines
US17/100,630 2020-11-20
US17/114,237 2020-12-07
US17/114,237 US11161892B1 (en) 2020-12-07 2020-12-07 Method of compact peptide vaccines using residue optimization
US17/336,960 US11235039B1 (en) 2020-11-20 2021-06-02 Immunogenic compositions comprising nucleic acids for RAS peptides
US17/336,960 2021-06-02
US17/389,875 US11421015B2 (en) 2020-12-07 2021-07-30 Method of compact peptide vaccines using residue optimization
US17/389,875 2021-07-30
US202163249235P 2021-09-28 2021-09-28
US63/249,235 2021-09-28
PCT/US2021/060013 WO2022109220A1 (en) 2020-11-20 2021-11-19 Compositions and methods for optimized peptide vaccines

Publications (3)

Publication Number Publication Date
JP2023551204A JP2023551204A (ja) 2023-12-07
JP2023551204A5 true JP2023551204A5 (enExample) 2024-10-28
JP7829242B2 JP7829242B2 (ja) 2026-03-13

Family

ID=81708071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530750A Active JP7829242B2 (ja) 2020-11-20 2021-11-19 最適化ペプチドワクチンの組成物および方法

Country Status (5)

Country Link
EP (1) EP4247401A4 (enExample)
JP (1) JP7829242B2 (enExample)
AU (1) AU2021381384A1 (enExample)
CA (1) CA3202227A1 (enExample)
WO (1) WO2022109220A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240131133A1 (en) * 2022-10-10 2024-04-25 Think Therapeutics, Inc. Compositions and methods for optimized kras peptide vaccines
CN116130005B (zh) * 2023-01-30 2023-06-16 深圳新合睿恩生物医疗科技有限公司 多表位疫苗的串联设计方法及装置、设备、存储介质

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884893B2 (en) * 2012-05-21 2018-02-06 Distributed Bio, Inc. Epitope focusing by variable effective antigen surface concentration
WO2016154047A2 (en) * 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
EP3294324A1 (en) * 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
CA2986235A1 (en) * 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
EP4159751A1 (en) 2016-08-02 2023-04-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-kras-g12d t cell receptors
EP3532070A1 (en) * 2016-10-26 2019-09-04 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3576764A4 (en) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
WO2019246286A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
WO2020210202A1 (en) 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) * 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization

Similar Documents

Publication Publication Date Title
CN107430132B (zh) 预测可用于疫苗接种的t细胞表位
ES2946072T3 (es) Vacunas individualizadas para el cáncer
JP2021040632A (ja) 免疫原性変異体ペプチドスクリーニングプラットフォーム
JP2021529750A5 (enExample)
JP2024517731A (ja) 残基の最適化による最適なペプチドワクチンの組成および方法
CN113383009A (zh) 制备疫苗组合物的方法
JP2024513781A5 (enExample)
US20230091256A1 (en) Hidden Frame Neoantigens
US20220148734A1 (en) Blood cell-free dna-based method for predicting prognosis of liver cancer treatment
CN113316818B (zh) 新生抗原的鉴定方法
CN112912403A (zh) 治疗肿瘤的方法
US20220036972A1 (en) A noise measure for copy number analysis on targeted panel sequencing data
JP7829242B2 (ja) 最適化ペプチドワクチンの組成物および方法
Chehal et al. Duodenal Metastasis from Colorectal Cancer: A Case Report
CN120464586A (zh) 一种用于罕少见基因突变的实体瘤治疗的重组溶瘤病毒
JP7775950B2 (ja) 情報処理システム及び情報処理方法
CN121287692A (zh) 花青素的新应用和抗肿瘤的组合物
CN121137158A (zh) 一种基于tcr库的肿瘤新抗原筛选方法
Killen et al. Configuration and rearrangement of the human GAGE gene clusters
Gan et al. Subglottic extramedullary plasmacytoma with light chain multiple myeloma masquerading as adult-onset asthma
Olafsson et al. DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon
HK40109445A (zh) 选择新表位作为具有增强效力的用於治疗的疾病特异性靶标
Kloor et al. Cancer in the light of evolution–from cancer genomes towards novel treatment and prevention approaches
Bonn Thalidomide: no benefit in myelofibrosis with myeloid metaplasia
SAHA SHIFTING PARADIGM IN GYNECOLOGICAL CANCER RESEARCH